Pancreatic Cancer Research

ResearcherFujian Medical UniversityActive in the last 2 years

Fengchun Lu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-9988-7216; OpenAlex author ID A5101086052. Sources: OpenAlex.

Their work

Papers
18 (first author 4, last author 6)
Trials
0
Grants
0
Labs led
1
Collaborators
26
Papers, trials and grants by year

2015: 1 paper · 2016: none · 2017: 1 paper · 2018: 1 paper · 2019: 2 papers · 2020: 1 paper · 2021: 2 papers · 2022: none · 2023: 5 papers · 2024: 1 paper · 2025: 1 paper · 2026: 3 papers

Papers 18

  1. CXCL10 drives pancreatic ductal adenocarcinoma progression through CXCR3-ERK/MAPK signaling. Last author DOI 10.1016/j.cellsig.2026.112637↗
  2. Single-Cell RNA-Seq Combined With Bulk RNA-Seq Revealed the Involvement of Pancreatic Cancer Tissue-Resident Macrophages in Tumour Progression and the Immunoth… Last author DOI 10.1111/jcmm.71212↗
  3. Cancer antigen 125 levels change rule after laparoscopic biopsy and its prognostic value for patients with unresectable pancreatic ductal adenocarcinoma: a ret… Last author DOI 10.1186/s12876-026-04688-7↗
  4. An exploratory study of serum creatine kinase as a prognostic marker for patients with resectable pancreatic cancer: looking into the relationship with body co… Last author DOI 10.1186/s12937-025-01084-x↗
  5. Loss of Annexin A1 in macrophages restrains efferocytosis and remodels immune microenvironment in pancreatic cancer by activating the cGAS/STING pathway. First author DOI 10.1136/jitc-2024-009318↗
  6. The cellular trajectories of tumor-associated macrophages decipher the heterogeneity of pancreatic cancer. First author DOI 10.1007/s10142-023-01266-y↗
  7. The CA125 level postoperative change rule and its prognostic significance in patients with resectable pancreatic cancer. Last author DOI 10.1186/s12885-023-11346-8↗
  8. A high serum creatine kinase (CK)-MB-to-total-CK ratio in patients with pancreatic cancer: a novel application of a traditional marker in predicting malignancy… Last author DOI 10.1186/s12957-023-02903-3↗
  9. High-dimensional single-cell analysis unveils distinct immune signatures of peripheral blood in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.3389/fendo.2023.1181538↗
  10. Single-cell RNA sequencing revealed subclonal heterogeneity and gene signatures of gemcitabine sensitivity in pancreatic cancer. Co-author DOI 10.3389/fphar.2023.1193791↗
  11. Laparoscopic biopsy and staging for locally advanced pancreatic cancer: experiences of 76 consecutive patients in a single institution. Co-author DOI 10.1007/s00423-021-02199-5↗
  12. Prognostic significance and therapeutic potential of the immune checkpoint VISTA in pancreatic cancer. Co-author DOI 10.1007/s00432-020-03463-9↗
  13. High-dimensional single-cell analysis delineates radiofrequency ablation induced immune microenvironmental remodeling in pancreatic cancer. Co-author DOI 10.1038/s41419-020-02787-1↗
  14. Synergistic inhibition of pancreatic cancer with anti-PD-L1 and c-Myc inhibitor JQ1. Co-author DOI 10.1080/2162402x.2019.1581529↗
  15. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer. First author DOI 10.1186/s13045-019-0822-6↗
  16. WIPF1 antagonizes the tumor suppressive effect of miR-141/200c and is associated with poor survival in patients with PDAC. First author DOI 10.1186/s13046-018-0848-6↗
  17. Neoadjuvant therapy prior to surgical resection for previously explored pancreatic cancer patients is associated with improved survival. Co-author DOI 10.21037/hbsn.2016.08.06↗
  18. Surgery for oligometastasis of pancreatic cancer. Co-author DOI 10.3978/j.issn.1000-9604.2015.05.02↗

Closest collaborators

The 25 strongest of 26 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Heguang Huang · 13 shared papers, 2018–2025 · strength 2.10
  2. Xianchao Lin · 11 shared papers, 2018–2026 · strength 1.79
  3. Yu Pan · 9 shared papers, 2018–2024 · strength 1.28
  4. Ronggui Lin · 6 shared papers, 2020–2026 · strength 1.23
  5. Congfei Wang · 4 shared papers, 2021–2026 · strength 0.89
  6. Zelin Hou · 6 shared papers, 2019–2024 · strength 0.86
  7. Cong Chen · 3 shared papers, 2023–2026 · strength 0.80
  8. Jiajing Lin · 4 shared papers, 2023–2024 · strength 0.79
  9. Xin Luo · 2 shared papers, 2023–2026 · strength 0.51
  10. Bin Wu · 1 shared paper, 2026 · strength 0.50
  11. Minggui Pan · 4 shared papers, 2018–2023 · strength 0.44
  12. Qinglin Fei · 4 shared papers, 2019–2021 · strength 0.41
  13. Haomin Yuan · 1 shared paper, 2026 · strength 0.39
  14. Wen Shi · 2 shared papers, 2023 · strength 0.34
  15. Yue Wu · 1 shared paper, 2026 · strength 0.32
  16. Tianhong Teng · 1 shared paper, 2025 · strength 0.25
  17. Jianfeng Gao · 1 shared paper, 2023 · strength 0.18
  18. Matthew John Weiss · 2 shared papers, 2015–2017 · strength 0.15
  19. Maoen Pan · 1 shared paper, 2018 · strength 0.09
  20. Katherine E. Poruk · 1 shared paper, 2015 · strength 0.08
  21. Jin Peng He · 1 shared paper, 2017 · strength 0.07
  22. Kevin C. Soares · 1 shared paper, 2017 · strength 0.07
  23. Neda Rezaee · 1 shared paper, 2017 · strength 0.07
  24. Christopher Lee Wolfgang · 1 shared paper, 2017 · strength 0.07
  25. Timothy Michael Pawlik · 1 shared paper, 2017 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.